• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » St. Jude’s deep brain stimulator proves effective against severe depression

St. Jude’s deep brain stimulator proves effective against severe depression

November 21, 2011 By MassDevice staff

Glowing Neuron image

St. Jude Medical’s (NYSE:STJ) deep brain stimulation implant proved safe and effective in treatment of patients with severe therapy-resistant depression.

Results from the first multi-center pilot study, conducted among 21 patients, found that 62 percent reported a 40 percent reduction in depression symptoms and 29 percent reported that their symptoms were cut in half after one year.

Study subjects received a Libra DBS implant near the collarbone, connected to small leads that deliver mild electrical pulses to an area of the brain called Brodmann Area 25, which is believed to regulate sleep, appetite, mood, anxiety, memory formation and self-esteem.

"The reduction in depression scores is clinically significant as these patients had previously tried multiple medications, psychotherapy and/or electroconvulsive therapy without success," primary investigator and neurosurgeon at Toronto Western Hospital Dr. Andres Lozano said in prepared remarks. "To see 62 percent of the patients in this study respond at one year gives us hope that this research may lead to a therapy for this hard-to-treat patient population."

Before DBS therapy, 70 percent of the enrolled patients were considered "severely or extremely ill" using the Clinical Global Impression of Severity rating scale. After 12 months more than 80 percent of patients showed improvement and none were rated severely or extremely ill, according to St. Jude.

Eight of the patients were able to return to their day-to-day lives and two patients were considered "in remission."

"These findings are significant as they confirm the basis on which we established the Broaden pivotal study," St. Jude Medical neuromodulation division president Rohan Hoare said in a press release. "These results add to the growing evidence suggesting that DBS therapy may help patients who currently don’t have an adequate treatment option in managing severe depression."

The St. Paul, Minn.-based health care giant’s Broaden study has FDA approval under an investigational device exemption to study stimulation in Brodmann Area 25 to determine whether it is a safe and effective treatment for severe depression. The FDA in July gave the study the green light to expand to 20 sites across the U.S. and 125 patients.  

St. Jude won CE Mark approval for its Athena deep brain stimulation programmer, designed to help physicians control the amount of current delivered to patients’ brains to treat Parkinson’s disease, in September 2010. The company landed Australian approval for that device in January 2011.

Boston Scientific Corp. (NYSE:BSX) is also deep into the neurostimulation and neuromodulation business, developing products for the treatment of hemorrhagic stroke, intracranial athero disease, and acute ischemic stroke.  Medtronic Inc. (NYSE:MDT)  launched its Activa device for the treatment of Parkinson’s disease earlier this year, after winning CE Mark approval in the European Union for it’s deep-brain stimulator for treatment of epilepsy last fall.

Filed Under: Neuromodulation/Neurostimulation, News Well Tagged With: Boston Scientific, Clinical Trials, Psychiatry, stjudemedical

More recent news

  • Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict
  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy